Failure of radioactive iodine in the treatment of hyperthyroidism
- PMID: 25001092
- PMCID: PMC4330099
- DOI: 10.1245/s10434-014-3858-4
Failure of radioactive iodine in the treatment of hyperthyroidism
Abstract
Background: Persistent or recurrent hyperthyroidism after treatment with radioactive iodine (RAI) is common and many patients require either additional doses or surgery before they are cured. The purpose of this study was to identify patterns and predictors of failure of RAI in patients with hyperthyroidism.
Methods: We conducted a retrospective review of patients treated with RAI from 2007 to 2010. Failure of RAI was defined as receipt of additional dose(s) and/or total thyroidectomy. Using a Cox proportional hazards model, we conducted univariate analysis to identify factors associated with failure of RAI. A final multivariate model was then constructed with significant (p < 0.05) variables from the univariate analysis.
Results: Of the 325 patients analyzed, 74 patients (22.8 %) failed initial RAI treatment, 53 (71.6 %) received additional RAI, 13 (17.6 %) received additional RAI followed by surgery, and the remaining 8 (10.8 %) were cured after thyroidectomy. The percentage of patients who failed decreased in a stepwise fashion as RAI dose increased. Similarly, the incidence of failure increased as the presenting T3 level increased. Sensitivity analysis revealed that RAI doses <12.5 mCi were associated with failure while initial T3 and free T4 levels of at least 4.5 pg/mL and 2.3 ng/dL, respectively, were associated with failure. In the final multivariate analysis, higher T4 (hazard ratio [HR] 1.13; 95 % confidence interval [CI] 1.02-1.26; p = 0.02) and methimazole treatment (HR 2.55; 95 % CI 1.22-5.33; p = 0.01) were associated with failure.
Conclusions: Laboratory values at presentation can predict which patients with hyperthyroidism are at risk for failing RAI treatment. Higher doses of RAI or surgical referral may prevent the need for repeat RAI in selected patients.
Figures
Similar articles
-
Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy.Thyroid. 2018 Sep;28(9):1111-1120. doi: 10.1089/thy.2017.0461. Epub 2018 Jul 23. Thyroid. 2018. PMID: 29882483
-
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.J Clin Endocrinol Metab. 2010 Jan;95(1):201-8. doi: 10.1210/jc.2009-1655. Epub 2009 Nov 11. J Clin Endocrinol Metab. 2010. PMID: 19906789
-
Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.Thyroid. 2019 Mar;29(3):322-331. doi: 10.1089/thy.2018.0315. Thyroid. 2019. PMID: 30667296
-
Graves' Disease: Can It Be Cured?Endocrinol Metab (Seoul). 2019 Mar;34(1):29-38. doi: 10.3803/EnM.2019.34.1.29. Endocrinol Metab (Seoul). 2019. PMID: 30912336 Free PMC article. Review.
-
Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.JAMA Netw Open. 2021 Sep 1;4(9):e2125072. doi: 10.1001/jamanetworkopen.2021.25072. JAMA Netw Open. 2021. PMID: 34533571 Free PMC article.
Cited by
-
Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population.Int J Endocrinol. 2016;2016:7863867. doi: 10.1155/2016/7863867. Epub 2016 Jun 29. Int J Endocrinol. 2016. PMID: 27446210 Free PMC article.
-
Radioiodine therapy and Graves' disease - Myths and reality.PLoS One. 2020 Jan 13;15(1):e0226495. doi: 10.1371/journal.pone.0226495. eCollection 2020. PLoS One. 2020. PMID: 31929534 Free PMC article.
-
Total versus near-total thyroidectomy in Graves' disease: a systematic review and meta-analysis of comparative studies.Gland Surg. 2021 Feb;10(2):729-738. doi: 10.21037/gs-20-757. Gland Surg. 2021. PMID: 33708555 Free PMC article.
-
Effectiveness of radioactive iodine (131I) in the treatment of Graves' disease: single center experience in Assiut University hospital.Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):235-242. eCollection 2020. Am J Nucl Med Mol Imaging. 2020. PMID: 33224619 Free PMC article.
-
[Ultrasound combined with Ki67 detection for analyzing contributing factors of failure to cure and recurrence of hyperthyroidism in patients with Graves disease after 131I treatment].Nan Fang Yi Ke Da Xue Xue Bao. 2022 Dec 20;42(12):1902-1906. doi: 10.12122/j.issn.1673-4254.2022.12.21. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 36651261 Free PMC article. Chinese.
References
-
- Astrup A, Buemann B, Christensen NJ, Madsen J, Gluud C, Bennett P, Svenstrup B. The contribution of body composition, substrates, and hormones to the variability in energy expenditure and substrate utilization in premenopausal women. J Clin Endocrinol Metab. 1992;74(2):279–286. - PubMed
-
- Wilber JF. Thyrotropin releasing hormone: secretion and actions. Annu Rev Med. 1973;24:353–364. - PubMed
-
- Siegel E, Tobias CA. Actions of thyroid hormones on cultured human cells. Nature. 1966;212(5068):1318–1321. - PubMed
-
- Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364(6):542–550. - PubMed
-
- Schussler-Fiorenza CM, Bruns CM, Chen H. The surgical management of Graves' disease. J Surg Res. 2006;133(2):207–214. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical